<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36733935</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model.</ArticleTitle><Pagination><StartPage>1083264</StartPage><MedlinePgn>1083264</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1083264</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.1083264</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Post-acute sequelae of COVID-19 seem to be an emerging global crisis. Machine learning radiographic models have great potential for meticulous evaluation of post-COVID-19 interstitial lung disease (ILD).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this multicenter, retrospective study, we included consecutive patients that had been evaluated 3 months following severe acute respiratory syndrome coronavirus 2 infection between 01/02/2021 and 12/5/2022. High-resolution computed tomography was evaluated through Imbio Lung Texture Analysis 2.1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Two hundred thirty-two (<i>n</i> = 232) patients were analyzed. FVC% predicted was &#x2265;80, between 60 and 79 and &lt;60 in 74.2% (<i>n</i> = 172), 21.1% (<i>n</i> = 49), and 4.7% (<i>n</i> = 11) of the cohort, respectively. DLCO% predicted was &#x2265;80, between 60 and 79 and &lt;60 in 69.4% (<i>n</i> = 161), 15.5% (<i>n</i> = 36), and 15.1% (<i>n</i> = 35), respectively. Extent of ground glass opacities was &#x2265;30% in 4.3% of patients (<i>n</i> = 10), between 5 and 29% in 48.7% of patients (<i>n</i> = 113) and &lt;5% in 47.0% of patients (<i>n</i> = 109). The extent of reticulation was &#x2265;30%, 5-29% and &lt;5% in 1.3% (<i>n</i> = 3), 24.1% (<i>n</i> = 56), and 74.6% (<i>n</i> = 173) of the cohort, respectively. Patients (<i>n</i> = 13, 5.6%) with fibrotic lung disease and persistent functional impairment at the 6-month follow-up received antifibrotics and presented with an absolute change of +10.3 (<i>p</i> = 0.01) and +14.6 (<i>p</i> = 0.01) in FVC% predicted at 3 and 6 months after the initiation of antifibrotic.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Post-COVID-19-ILD represents an emerging entity. A substantial minority of patients presents with fibrotic lung disease and might experience benefit from antifibrotic initiation at the time point that fibrotic-like changes are "immature." Machine learning radiographic models could be of major significance for accurate radiographic evaluation and subsequently for the guidance of therapeutic approaches.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Karampitsakos, Sotiropoulou, Katsaras, Tsiri, Georgakopoulou, Papanikolaou, Bibaki, Tomos, Lambiri, Papaioannou, Zarkadi, Antonakis, Pandi, Malakounidou, Sampsonas, Makrodimitri, Chrysikos, Hillas, Dimakou, Tzanakis, Sipsas, Antoniou and Tzouvelekis.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karampitsakos</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotiropoulou</LastName><ForeName>Vasilina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsaras</LastName><ForeName>Matthaios</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsiri</LastName><ForeName>Panagiota</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Georgakopoulou</LastName><ForeName>Vasiliki E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases-COVID-19 Unit, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papanikolaou</LastName><ForeName>Ilias C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Corfu General Hospital, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibaki</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Pneumonology, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomos</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>5th Department of Respiratory Medicine, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambiri</LastName><ForeName>Irini</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Pneumonology, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papaioannou</LastName><ForeName>Ourania</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarkadi</LastName><ForeName>Eirini</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonakis</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Corfu General Hospital, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandi</LastName><ForeName>Aggeliki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Corfu General Hospital, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malakounidou</LastName><ForeName>Elli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampsonas</LastName><ForeName>Fotios</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makrodimitri</LastName><ForeName>Sotiria</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases-COVID-19 Unit, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrysikos</LastName><ForeName>Serafeim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>5th Department of Respiratory Medicine, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillas</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>5th Department of Respiratory Medicine, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimakou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>5th Department of Respiratory Medicine, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzanakis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Pneumonology, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sipsas</LastName><ForeName>Nikolaos V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases-COVID-19 Unit, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, National and Kapodistrian University of Athens, Zografou, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoniou</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Cellular Pneumonology, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzouvelekis</LastName><ForeName>Argyris</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University General Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Med (Lausanne). 2023 Apr 13;10:1194925. doi: 10.3389/fmed.2023.1194925</RefSource><PMID Version="1">37122328</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antifibrotics</Keyword><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword></KeywordList><CoiStatement>AT has received grants and honoraria from GlaxoSmithKline, Astra Zeneca, Chiesi, Roche, and Boehringer Ingelheim outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CB declared a shared affiliation, with no collaboration, with the authors to the handling editor at the time of the review.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36733935</ArticleId><ArticleId IdType="pmc">PMC9886681</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.1083264</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708&#x2013;20. 10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos A, et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. (2022). 10.1101/2022.06.13.22276211 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.13.22276211</ArticleId><ArticleId IdType="pmc">PMC9636985</ArticleId><ArticleId IdType="pubmed">36273769</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T, Malakounidou E, Papaioannou O, Dimakopoulou V, Zarkadi E, Katsaras M, et al. Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study. Respir Res. (2021) 22:317. 10.1186/s12931-021-01914-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01914-6</ArticleId><ArticleId IdType="pmc">PMC8692825</ArticleId><ArticleId IdType="pubmed">34937570</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehar S, Boushra M, Ntiamoah P, Biehl M. Post-acute sequelae of SARS-CoV-2 infection: caring for the &#x2018;long-haulers&#x2019;. Cleve Clin J Med. (2021) 88:267&#x2013;72. 10.3949/ccjm.88a.21010</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.88a.21010</ArticleId><ArticleId IdType="pubmed">33941600</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert S, Zimmermann L, Shi X, Fritsche L, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. (2022) 226:1593&#x2013;607. 10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P, Casari G, Townsend L, O&#x2019;Farrelly C, Tancevski I, L&#xf6;ffler-Ragg J, et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. (2022) 28:879&#x2013;82. 10.1038/s41591-022-01766-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Talwar A, Lee JTA. Proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. (2020) 324:2251&#x2013;2. 10.1001/jama.2020.22717</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22717</ArticleId><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. (2021) 9:129. 10.1016/S2213-2600(21)00031-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan M, McGroder C, Stevens J, et al. Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Culebras M, Loor K, Sansano I, Persiva &#xd3;, Clofent D, Polverino E, et al. Histological findings in transbronchial cryobiopsies obtained from patients after COVID-19. Chest. (2022) 161:647&#x2013;50. 10.1016/j.chest.2021.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.09.016</ArticleId><ArticleId IdType="pmc">PMC8464080</ArticleId><ArticleId IdType="pubmed">34582842</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourki B, Vera I, Perrot C, Farsaei F, Arsenault A, Juan-Guardela B, et al. Peripheral blood gene expression changes predict mortality and treatment response in acute Covid-19 and associate with lung fibrosis. C32 interrogation of genetic variation, gene expression, and other biological layers with omics techniques to understand respiratory traits. Am J Respir Crit Care Med. (2022) 205:A3929. 10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3929</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3929</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutou A, Asimakos A, Kortianou E, Vogiatzis I, Tzouvelekis A. Long COVID-19 pulmonary sequelae and management considerations. J Pers Med. (2021) 11:838. 10.3390/jpm11090838</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11090838</ArticleId><ArticleId IdType="pmc">PMC8469288</ArticleId><ArticleId IdType="pubmed">34575615</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutou A, Georgopoulou A, Pitsiou G, Stanopoulos I, Kontakiotis T, Kioumis I. Changes in the respiratory function of COVID-19 survivors during follow-up: a novel respiratory disorder on the rise? Int J Clin Pract. (2021) 75:e14301. 10.1111/ijcp.14301</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14301</ArticleId><ArticleId IdType="pmc">PMC8236973</ArticleId><ArticleId IdType="pubmed">33932073</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T, Kalogeropoulou C, Tzilas V, Papaioannou O, Kazantzi A, Koukaki E, et al. Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases: insights from a machine learning radiographic model. Respiration. (2022) 101:262&#x2013;71. 10.1159/000519215</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000519215</ArticleId><ArticleId IdType="pubmed">34592744</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin D. Deep learning and the evaluation of pulmonary fibrosis. Lancet Respir Med. (2018) 6:803&#x2013;5. 10.1016/S2213-2600(18)30371-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(18)30371-0</ArticleId><ArticleId IdType="pmc">PMC6293056</ArticleId><ArticleId IdType="pubmed">30232047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez G, Ash S. Disease staging and prognosis in smokers using deep learning in chest computed tomography. Am J Respir Crit Care Med. (2018) 197:193&#x2013;203. 10.1164/rccm.201705-0860OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201705-0860OC</ArticleId><ArticleId IdType="pmc">PMC5768902</ArticleId><ArticleId IdType="pubmed">28892454</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh S, Calandriello L, Silva M, Sverzellati N. Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study. Lancet Respir Med. (2018) 6:837&#x2013;45. 10.1016/S2213-2600(18)30286-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(18)30286-8</ArticleId><ArticleId IdType="pubmed">30232049</ArticleId></ArticleIdList></Reference><Reference><Citation>Salisbury M, Lynch D, van Beek E, Kazerooni E, Guo J, Xia M, et al. Idiopathic pulmonary fibrosis: the association between the adaptive multiple features method and fibrosis outcomes. Am J Respir Crit Care Med. (2017) 195:921&#x2013;9. 10.1164/rccm.201607-1385OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201607-1385OC</ArticleId><ArticleId IdType="pmc">PMC5387708</ArticleId><ArticleId IdType="pubmed">27767347</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado F, Moua T, Rajagopalan S, Karwoski R, Raghunath S, Decker P, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J. (2014) 43:204&#x2013;12. 10.1183/09031936.00071812</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00071812</ArticleId><ArticleId IdType="pubmed">23563264</ArticleId></ArticleIdList></Reference><Reference><Citation>Trusculescu A, Manolescu D, Tudorache E, Oancea C. Deep learning in interstitial lung disease&#x2014;how long until daily practice. Eur Radiol. (2020) 30:6285&#x2013;92. 10.1007/s00330-020-06986-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-020-06986-4</ArticleId><ArticleId IdType="pmc">PMC7554005</ArticleId><ArticleId IdType="pubmed">32537728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch D, Sverzellati N, Travis W, Brown K, Colby T, Galvin J, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper. Lancet Respir Med. (2018) 6:138&#x2013;53. 10.1016/S2213-2600(17)30433-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(17)30433-2</ArticleId><ArticleId IdType="pubmed">29154106</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu GR-JM, Myers J, Richeldi L, Ryerson C, Lederer D, Behr J, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2018) 198:e44&#x2013;68. 10.1164/rccm.201807-1255ST</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201807-1255ST</ArticleId><ArticleId IdType="pubmed">30168753</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G, Remy-Jardin M, Ryerson C, Myers J, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2020) 202:e36&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7397797</ArticleId><ArticleId IdType="pubmed">32706311</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall K, Mukherjee B, Castanheira A, Lam J, Benedetti G, Mak S, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. (2021) 18:799&#x2013;806. 10.1513/AnnalsATS.202008-1002OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1002OC</ArticleId><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart I, Jacob J, George P, Molyneaux P, Porter J, Allen R, et al. Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study. medRxiv [Preprint]. (2022). 10.1101/2022.03.10.22272081</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.10.22272081</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomassetti S, Oggionni T, Barisione E, Bargagli E, Bonifazi M, Confalonieri M, et al. A multidisciplinary multicenter study evaluating risk factors, prevalence and characteristics of post-Covid-19 interstitial lung syndrome (PCOILS). Eur Respir J. (2021) 58(Suppl. 65):OA1567. 10.1183/13993003.congress-2021.OA1567</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.congress-2021.OA1567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravaglia C, Doglioni C, Chilosi M, Piciucchi S, Dubini A, Rossi G, et al. Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur Respir J. (2022) 60:2102411. 10.1183/13993003.02411-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02411-2021</ArticleId><ArticleId IdType="pmc">PMC8932282</ArticleId><ArticleId IdType="pubmed">35301248</ArticleId></ArticleIdList></Reference><Reference><Citation>Cau R, Faa G, Nardi V, Balestrieri A, Puig J, Suri J, et al. Long-COVID diagnosis: from diagnostic to advanced AI-driven models. Eur J Radiol. (2022) 148:110164. 10.1016/j.ejrad.2022.110164</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2022.110164</ArticleId><ArticleId IdType="pmc">PMC8791239</ArticleId><ArticleId IdType="pubmed">35114535</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarraso J, Safont B, Carbonell-Asins J, Fernandez-Fabrellas E, Sancho-Chust J, Naval E, et al. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. Respir Res. (2022) 23:242. 10.1186/s12931-022-02166-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02166-8</ArticleId><ArticleId IdType="pmc">PMC9466319</ArticleId><ArticleId IdType="pubmed">36096801</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. (2021) 299:E177&#x2013;86. 10.1148/radiol.2021203153</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso D, Guido G, Zerunian M, Polidori T, Lucertini E, Pucciarelli F, et al. Post-acute sequelae of COVID-19 pneumonia: six-month chest CT follow-up. Radiology. (2021) 301:E396&#x2013;405. 10.1148/radiol.2021210834</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021210834</ArticleId><ArticleId IdType="pmc">PMC8335814</ArticleId><ArticleId IdType="pubmed">34313468</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. (2021) 398:747&#x2013;58. 10.1016/S0140-6736(21)01755-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis T, Heiden E, Horno J, Welham B, Burke H, Freeman A, et al. Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. Respir Res. (2021) 22:157. 10.1186/s12931-021-01750-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01750-8</ArticleId><ArticleId IdType="pmc">PMC8139368</ArticleId><ArticleId IdType="pubmed">34020644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki E, Matralis A, Tzouvelekis A, et al. Commonalities between ARDS. pulmonary fibrosis and COVID-19: the potential of autotaxin as a therapeutic target. Front Immunol. (2021) 12:687397. 10.3389/fimmu.2021.687397</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.687397</ArticleId><ArticleId IdType="pmc">PMC8522582</ArticleId><ArticleId IdType="pubmed">34671341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Yim J, Park J. Pulmonary function and chest computed tomography abnormalities 6&#x2013;12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res. (2022) 23:233. 10.1186/s12931-022-02163-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02163-x</ArticleId><ArticleId IdType="pmc">PMC9446643</ArticleId><ArticleId IdType="pubmed">36068582</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J. (2021) 58:2101956. 10.1183/13993003.01956-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01956-2021</ArticleId><ArticleId IdType="pmc">PMC8637181</ArticleId><ArticleId IdType="pubmed">34857587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocconcelli E, Bernardinello N, Giraudo C, Castelli G, Giorgino A, Leoni D, et al. Characteristics and prognostic factors of pulmonary fibrosis after COVID-19 pneumonia. Front Med. (2022) 8:823600. 10.3389/fmed.2021.823600</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.823600</ArticleId><ArticleId IdType="pmc">PMC8841677</ArticleId><ArticleId IdType="pubmed">35174188</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen D, Ng R, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. (2022) 185:881&#x2013;95.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhooria S, Chaudhary S, Sehgal I, Agarwal R, Arora S, Garg M, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J. (2022) 59:2102930. 10.1183/13993003.02930-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02930-2021</ArticleId><ArticleId IdType="pmc">PMC8850687</ArticleId><ArticleId IdType="pubmed">34887325</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, Zhang X, Jia X, Zheng Y, et al. Fibrotic interstitial lung abnormalities at 1-year follow-up CT after severe COVID-19. Radiology. (2021) 301:E438&#x2013;40. 10.1148/radiol.2021210972</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021210972</ArticleId><ArticleId IdType="pmc">PMC8335811</ArticleId><ArticleId IdType="pubmed">34313470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri L, Moss S, Khan F, Chi W, Xia J, Robinson K, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. (2022). 10.1101/2021.03.15.21253593 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.15.21253593</ArticleId><ArticleId IdType="pubmed">35338102</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine.
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia (PINCER). Available online at: https://clinicaltrials.gov/ct2/show/NCT04856111</Citation></Reference><Reference><Citation>U.S. National Library of Medicine.
Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis (NINTECOR). Available online at: https://clinicaltrials.gov/ct2/show/NCT04541680</Citation></Reference><Reference><Citation>U.S. National Library of Medicine.
Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19 (FIBRO-COVID). Available online at: https://clinicaltrials.gov/ct2/show/NCT04607928</Citation></Reference><Reference><Citation>Singh P, Behera D, Gupta S, Deep A, Priyadarshini S, Padhan P. Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: a single-centre study. J R Coll Physicians Edinb. (2022) 52:100&#x2013;4. 10.1177/14782715221103402</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14782715221103402</ArticleId><ArticleId IdType="pubmed">36146989</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura Y, Mitsuyama Y, Minami K, Nishida T, Watanabe A, Okada N, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study. Int J Infect Dis. (2021) 108:454&#x2013;60. 10.1016/j.ijid.2021.05.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.05.055</ArticleId><ArticleId IdType="pmc">PMC8146615</ArticleId><ArticleId IdType="pubmed">34048887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian S, Farhadi T, Varahram M, Velayati A. Nintedanib: a review of the properties, function, and usefulness to minimize COVID-19 induced lung injury. Expert Rev Anti Infect Ther. (2022) 1&#x2013;8. 10.1080/14787210.2023.2153116 [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2023.2153116</ArticleId><ArticleId IdType="pubmed">36440472</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa G, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. (2020) 8:750&#x2013;2. 10.1016/S2213-2600(20)30222-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30222-8</ArticleId><ArticleId IdType="pmc">PMC7228737</ArticleId><ArticleId IdType="pubmed">32422177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells A, Devaraj A, Desai S. Interstitial lung disease after COVID-19 infection: a catalog of uncertainties. Radiology. (2021) 299:E216&#x2013;8. 10.1148/radiol.2021204482</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021204482</ArticleId><ArticleId IdType="pmc">PMC7841875</ArticleId><ArticleId IdType="pubmed">33502279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells A, Devaraj A. Residual lung disease at six-month follow-up CT after COVID-19: clinical significance is a key issue. Radiology. (2021) 301:E406&#x2013;8. 10.1148/radiol.2021211284</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021211284</ArticleId><ArticleId IdType="pmc">PMC8335810</ArticleId><ArticleId IdType="pubmed">34313479</ArticleId></ArticleIdList></Reference><Reference><Citation>Barini M, Percivale I, Danna P, Longo V, Costantini P, Paladini A, et al. 18 months computed tomography follow-up after Covid-19 interstitial pneumonia. J Public Health Res. (2022) 11:2782. 10.4081/jphr.2022.2782</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/jphr.2022.2782</ArticleId><ArticleId IdType="pmc">PMC8973211</ArticleId><ArticleId IdType="pubmed">35315262</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>